The Steering Committee
Alastair Carruthers, MD, FRCP(C)
You need to upgrade your Flash Player
|
You need to upgrade your Flash Player to view this content.
What's New
|
• Interactive case study on volumizing with dermal fillers available now!
Our newest case study, developed with Steering Committee Member Mark L. Jewell, MD, explores treatment options for the off-label use of dermal fillers for mid-face volumizing. Upon completion of the case study, posttest, and evaluation form, you'll receive 1,0 AMA PRA Category 1 Credit instantly!
|
|
|
• New CME Webinar!
Current Concepts in Facial Aesthetics: Consensus Recommendations for Botulinum Toxin Type A (BoNTA) and Hyaluronic Acid (HA) Fillers is a CME Webinar archive featuring Drs Steven Fagien, Steven Dayan, and Jessica Wu. Presentations focus on best practices for BoNTA and HA Fillers used alone and in combination for the upper, middle, and lower face.
|
|
|
• Ask The Expert
Steering Committee Members Kevin C. Smith, MD, FRCP(C), and Mark L. Jewell, MD, address questions regarding reconstitution of botulinum toxin type A (BoNTA) for the off-label use of facial hyperhidrosis, non–animal-stabilized hyaluronic acid for the off-label use of tear trough deformity, and the off-label use of dermal fillers for lip enhancement, among other topics.
|
|
|
• Clinical Literature Overviews
The latest current literature entries explore complications after the use of polymethylmethacrylate injections, results from the Injectable Filler Safety (IFS) study, and the effects of non–animal-stabilized hyaluronic acid on facial aging, among other important topics. Also featured: Expert commentary from Steering Committee Member Mark L. Jewell, MD!
|
|
|
• Dynamic Slide Library
New slides exploring the efficacy of non–animal-stabilized hyaluronic acid, hyaluronic acid gel, and bovine and porcine collagen for the optimal treatment of nasolabial folds.
|
|
|
• Patient-Education Materials
Choosing Wisely, our series of patient-education handouts, designed to assist you with patient management.
|
Slides of the Month
|
|
|
|
|
|
|
|
Hyaluronic Acid Versus Bovine Collagen for Nasolabial Folds
|
|
This multicenter, double-masked, randomized, within-subject study compared the efficacy ...
|
|
View
all Slides |
|
|
|
|
|
|
Mean Improvement from Baseline: Investigators’ Assessment
|
|
In this study, 439 patients (aged ≥30 years) who had moderate or severe (fully visibl...
|
|
View
all Slides |
|
|
|
|
|
|
Mean Improvement from Baseline: Patients’ Assessment
|
|
In this study, 439 patients (aged ≥30 years) who had moderate or severe (fully visibl...
|
|
View
all Slides |
|
|
|
|
|
|
NASHA Versus Porcine Collagen for Nasolabial Folds
|
|
This randomized, multicenter, within-subject, noninferiority study compared the efficacy...
|
|
View
all Slides |
|
|
|
|
|
|
Wrinkle Scale After Optimal Cosmetic Correction
|
|
This randomized, multicenter, within-subject, noninferiority study compared the efficacy...
|
|
View
all Slides |
|
In The News
BDA Response To NHS Next Stage Review, UK
Jul 04, 2008 -- The British Dental Association has noted the recognition of the importance placed on dentistry in the NHS Next Stage Review, published today by the Department of Health. The review is published just one day after the Department of Health was criticised for the failures of the new dental contract by the Health Select Committee.
|
FDA Approves EVOLENCE, A New Generation Collagen Based Facial Filler
Jul 04, 2008 -- The U.S. Food and Drug Administration ("FDA") announced the approval of EVOLENCE for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds. EVOLENCE is a new advanced collagen-based structural dermal filler, and a first of its kind product. The introduction of EVOLENCE marks the first dermal filler entry for the Aesthetics Group of OrthoNeutrogena.
|
Breakthrough Technology That Will Revolutionize The Treatment Of Tooth Decay
Jul 04, 2008 -- Quantum Dental Technologies, a Canadian diagnostic device company, revealed its breakthrough technology which detects and monitors the early onset of tooth decay without the need for dental x-rays. It reduces the number of invasive and painful procedures, and encourages better oral health. Quantum introduced its Dental Caries Detection System prototype, known as The Canary System, at the International Association for Dental Research (IADR) Conference in Toronto, Canada.
|
VioQuest Pharmaceuticals Submits 510(k) Application To FDA For Xyfid?, A Novel Topical Agent For The Treatment Of Various Skin Disorders
Jul 03, 2008 -- VioQuest Pharmaceuticals (OTCBB: VOQP) announced the submission of a 510(k) application to the United States Food and Drug Administration (FDA).
|
|
|
|
Login
Please enter both email and password to log in
Participate in our
Online polls
|
|